advertisement
Abstract #8272 Published in IGR 4-3
The short-term IOP-lowering effect of brimonidine 0.2% and dorzolamide 2% combination in primary open-angle glaucoma
Samet Ermis S; Ozturk F; Ubeyt Inan UActa Ophthalmologica Scandinavica 2002; 80: 632-634
PURPOSE: To evaluate the ocular hypotensive effect of dorzolamide 2% in primary open-angle glaucoma (POAG) patients with intraocular pressure (IOP) of at least 22 mmHg, despite ongoing twice daily treatment with brimonidine 0.2%. PATIENTS AND METHODS: Nineteen eyes of 19 patients with POAG and IOP ≥ 22 mmHg, on twice daily brimonidine therapy, were included in the study. IOP and adverse effects were recorded on days 1, 7, 14, and 30 after adding dorzolamide three times daily to the treatment. RESULTS: mean pretreatment IOP was 27.6 ± 2.2 mmHg. This decreased to 24.2 ± 2.2 mmHg after a mean duration of 23.8 ± 12.1 days. After dorzolamide was added to the treatment, mean IOP was 20.8 ± 2.3 mmHg on day 2, 19.3 ± 2.2 mmHg on day 7, 18.0 ± 2.5 mmHg on day 14, and 17.2 ± 2.3 mmHg on day 20. The differences between pre- and post-treatment IOP values were statistically significant (p < 0.0001, ANNOVA test). CONCLUSION: Dorzolamide administered three times daily has a significant additive ocular hypotensive effect in POAG patients whose IOP is elevated, despite ongoing treatment with brimonidine.
S. Samet Ermis, MD, Department of Ophthalmology, School of Medicine, University of Afyon Kocatepe, Afyon, Turkey
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
